Literature DB >> 16636283

Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting.

Edmund A Rossi1, David M Goldenberg, Thomas M Cardillo, William J McBride, Robert M Sharkey, Chien-Hsing Chang.   

Abstract

We describe a platform technology, termed the dock and lock method, which uses a natural binding between the regulatory subunits of cAMP-dependent protein kinase and the anchoring domains of A kinase anchor proteins for general application in constructing bioactive conjugates of different protein and nonprotein molecules from modular subunits on demand. This approach could allow quantitative and site-specific coupling of many different biological substances for diverse medical applications. The dock and lock method is validated herein by producing bispecific, trivalent-binding complexes composed of three stably linked Fab fragments capable of selective delivery of radiotracers to human cancer xenografts, resulting in rapid, significantly improved cancer targeting and imaging, providing tumor/blood ratios from 66 +/- 5 at 1 h to 395 +/- 26 at 24 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16636283      PMCID: PMC1447525          DOI: 10.1073/pnas.0600982103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands.

Authors:  Christian D Hodneland; Young-Sam Lee; Dal-Hee Min; Milan Mrksich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  Bioinformatic design of A-kinase anchoring protein-in silico: a potent and selective peptide antagonist of type II protein kinase A anchoring.

Authors:  Neal M Alto; Scott H Soderling; Naoto Hoshi; Lorene K Langeberg; Rosa Fayos; Patricia A Jennings; John D Scott
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

3.  Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.

Authors:  R B Pepinsky; D J LePage; A Gill; A Chakraborty; S Vaidyanathan; M Green; D P Baker; E Whalley; P S Hochman; P Martin
Journal:  J Pharmacol Exp Ther       Date:  2001-06       Impact factor: 4.030

4.  Design of multivalent complexes using the barnase*barstar module.

Authors:  Sergey M Deyev; Robert Waibel; Ekaterina N Lebedenko; August P Schubiger; Andreas Plückthun
Journal:  Nat Biotechnol       Date:  2003-11-23       Impact factor: 54.908

5.  Improving the intein-mediated, site-specific protein biotinylation strategies both in vitro and in vivo.

Authors:  Lay-Pheng Tan; Rina Y P Lue; Grace Y J Chen; Shao Q Yao
Journal:  Bioorg Med Chem Lett       Date:  2004-12-20       Impact factor: 2.823

6.  Analysis of A-kinase anchoring protein (AKAP) interaction with protein kinase A (PKA) regulatory subunits: PKA isoform specificity in AKAP binding.

Authors:  F W Herberg; A Maleszka; T Eide; L Vossebein; K Tasken
Journal:  J Mol Biol       Date:  2000-04-28       Impact factor: 5.469

7.  Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen.

Authors:  H Karacay; R M Sharkey; W J McBride; G L Griffiths; Z Qu; K Chang; H J Hansen; D M Goldenberg
Journal:  Bioconjug Chem       Date:  2002 Sep-Oct       Impact factor: 4.774

8.  Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.

Authors:  Robert M Sharkey; Habibe Karacay; Heidi Richel; William J McBride; Edmund A Rossi; Ken Chang; Dion Yeldell; Gary L Griffiths; Hans J Hansen; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

9.  Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy.

Authors:  Edmund A Rossi; Robert M Sharkey; William McBride; Habibe Karacay; Li Zeng; Hans J Hansen; David M Goldenberg; Chien-Hsing Chang
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

10.  A universal pretargeting system for cancer detection and therapy using bispecific antibody.

Authors:  Robert M Sharkey; William J McBride; Habibe Karacay; Ken Chang; Gary L Griffiths; Hans J Hansen; David M Goldenberg
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

View more
  75 in total

1.  Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.

Authors:  Birgit Meller; Margarete Rave-Fränck; Christian Breunig; Markus Schirmer; Manfred Baehre; Roger Nadrowitz; Torsten Liersch; Johannes Meller
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

Review 2.  Cancer therapy with bispecific antibodies: Clinical experience.

Authors:  Archana Thakur; Lawrence G Lum
Journal:  Curr Opin Mol Ther       Date:  2010-06

3.  New lyophilized kit for rapid radiofluorination of peptides.

Authors:  William J McBride; Christopher A D'Souza; Habibe Karacay; Robert M Sharkey; David M Goldenberg
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

4.  Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap.

Authors:  M Jules Mattes; Rosana B Michel; David M Goldenberg; Robert M Sharkey
Journal:  Cancer Biother Radiopharm       Date:  2009-04       Impact factor: 3.099

5.  Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?

Authors:  Caroline Rousseau; Françoise Kraeber-Bodéré; Jacques Barbet; Jean-François Chatal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09       Impact factor: 9.236

Review 6.  Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy.

Authors:  Robert M Sharkey; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Semin Nucl Med       Date:  2010-05       Impact factor: 4.446

7.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

Review 8.  Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

Authors:  Patrick Chames; Daniel Baty
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

9.  Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.

Authors:  Robert M Sharkey; Habibe Karacay; Samuel Litwin; Edmund A Rossi; William J McBride; Chien-Hsing Chang; David M Goldenberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

10.  Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.

Authors:  Catharina M van Rij; Cathelijne Frielink; David M Goldenberg; Robert M Sharkey; Gerben M Franssen; Susanne Lütje; William J McBride; Wim J G Oyen; Otto C Boerman
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.